Barinthus Biotherapeutics (BRNS) Prepaid Assets (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Prepaid Assets came in at $194000.0 in Q1 2026, down 55.4% YoY from $435000.0 in Q1 2025, and up 68.7% on a QoQ basis from $115000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Prepaid Assets (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Prepaid Assets data on file, last reported at $194000.0 in Q1 2026.
- Quarterly Prepaid Assets fell 55.4% year-over-year to $194000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $194000.0 (down 55.4% YoY) and the FY2025 annual result came in at $115000.0, down 66.57% from the prior year.
- Prepaid Assets climbed to $194000.0 in Q1 2026, from $115000.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $9.9 million in Q2 2022 to a low of $115000.0 in Q4 2025.
- A 5-year average of $4.3 million and a median of $5.9 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets surged 1521.44% — and 2024, when it tumbled 96.53%.
- Tracing BRNS's Prepaid Assets over 5 years: stood at $611000.0 in 2022, then soared by 1521.44% to $9.9 million in 2023, then plunged by 96.53% to $344000.0 in 2024, then sank by 66.57% to $115000.0 in 2025, then surged by 68.7% to $194000.0 in 2026.
- The last three Prepaid Assets figures came in at $194000.0 (Q1 2026), $115000.0 (Q4 2025), and $663000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.36 Mn |
| Mar 31, 2026 | 194,000.00 |
| Dec 31, 2025 | 115,000.00 |
| Sep 30, 2025 | 663,000.00 |
| Jun 30, 2025 | 7.68 Mn |
| Mar 31, 2025 | 435,000.00 |
| Dec 31, 2024 | 344,000.00 |
| Sep 30, 2024 | 464,000.00 |
| Jun 30, 2024 | 626,000.00 |
| Mar 31, 2024 | 7.96 Mn |
| Dec 31, 2023 | 9.91 Mn |
| Sep 30, 2023 | 6.58 Mn |
| Jun 30, 2023 | 6.76 Mn |
| Mar 31, 2023 | 5.90 Mn |
| Dec 31, 2022 | 611,000.00 |
| Sep 30, 2022 | 8.25 Mn |
| Jun 30, 2022 | 9.94 Mn |
| Mar 31, 2022 | 7.40 Mn |
| Dec 31, 2021 | 6.46 Mn |
| Sep 30, 2021 | 6.68 Mn |